David John Mott
David John Mott
Office of Health Economics
Verifierad e-postadress på ohe.org - Startsida
Citeras av
Citeras av
Incorporating quantitative patient preference data into healthcare decision making processes: is HTA falling behind?
DJ Mott
The Patient-Patient-Centered Outcomes Research 11 (3), 249-252, 2018
Valuing EQ-5D-Y-3L health states using a discrete choice experiment: do adult and adolescent preferences differ?
DJ Mott, KK Shah, JM Ramos-Goñi, NJ Devlin, O Rivero-Arias
Medical Decision Making 41 (5), 584-596, 2021
Accounting for preference heterogeneity in discrete-choice experiments: an ISPOR special interest group report
C Vass, M Boeri, S Karim, D Marshall, B Craig, KA Ho, D Mott, ...
Value in Health 25 (5), 685-694, 2022
EQ-5D-Y Value Set for Germany
S Kreimeier, D Mott, K Ludwig, W Greiner, IHTAH Group
PharmacoEconomics, 2022
Whose preferences should be elicited for use in health-care decision-making? A case study using anticoagulant therapy
DJ Mott, M Najafzadeh
Expert Review of Pharmacoeconomics & Outcomes Research 16 (1), 33-39, 2016
Reporting quality of marginal rates of substitution in discrete choice experiments that elicit patient preferences
DJ Mott, N Chami, T Tervonen
Value in Health 23 (8), 979-984, 2020
Considering severity in health technology assessment: can we do better?
C Skedgel, N Henderson, A Towse, D Mott, C Green
Value in Health 25 (8), 1399-1403, 2022
A European, prospective, observational study of enzalutamide in patients with metastatic castration-resistant prostate cancer: PREMISE
H Payne, A Robinson, B Rappe, S Hilman, U De Giorgi, S Joniau, ...
International Journal of Cancer, 2021
Challenges in valuing temporary health states for economic evaluation: a review of empirical applications of the chained time trade-off method
J Stoniute, DJ Mott, J Shen
Value in Health 21 (5), 605-611, 2018
Does changing the age of a child to be considered in 3-level version of EQ-5D-Y discrete choice experiment–based valuation studies affect health preferences?
JM Ramos-Goñi, A Estévez-Carrillo, O Rivero-Arias, D Rowen, D Mott, ...
Value in Health 25 (7), 1196-1204, 2022
Conducting a time trade-off study alongside a clinical trial: a case study and recommendations
J Shen, S Hill, D Mott, M Breckons, L Vale, R Pickard
PharmacoEconomics-Open 3, 5-20, 2019
Criteria for developing, assessing and selecting candidate EQ-5D bolt-ons
BJ Mulhern, C Sampson, P Haywood, R Addo, K Page, D Mott, K Shah, ...
Quality of Life Research 31 (10), 3041-3048, 2022
Resource allocation in public sector programmes: does the value of a life differ between governmental departments?
P Cubi-Molla, D Mott, N Henderson, B Zamora, M Grobler, M Garau
Cost Effectiveness and Resource Allocation 21 (1), 96, 2023
A multinational European study of patient preferences for novel diagnostics to manage antimicrobial resistance
DJ Mott, G Hampson, MJ Llewelyn, J Mestre-Ferrandiz, MM Hopkins
Applied Health Economics and Health Policy 18, 69-79, 2020
Estimating latent scale discrete choice utilities to develop an EQ-5D-Y value set in the UK
O Rivero-Arias, KK Shah, JM Ramos-Goñi, D Mott, N Develin
Barcelona: EuroQoL Plenary, 2017
Do preferences differ based on respondent experience of a health issue and its treatment? A case study using a public health intervention
DJ Mott, L Ternent, L Vale
The European Journal of Health Economics 24 (3), 413-423, 2023
Public preferences for health gains and cures: a discrete choice experiment
G Hampson, D Mott, N Devlin, K Shah
Office of Health Economics, 2019
Analytical considerations when anchoring discrete choice experiment values using composite time trade-off data: the case of EQ-5D-Y-3L
DJ Mott, NJ Devlin, S Kreimeier, R Norman, KK Shah, O Rivero-Arias
Pharmacoeconomics 40 (Suppl 2), 129-137, 2022
PCN382-quality of life in long-term cancer survivors: implications for future health technology assessments in oncology
P Cubi-Molla, DJ Mott, K Shah, M Herdman, Y Summers, C Tsuchiya, ...
Value in Health 21, S79, 2018
Modelling spillover effects on informal carers: the Carer QALY trap
DJ Mott, H Schirrmacher, H Al-Janabi, S Guest, B Pennington, N Scheuer, ...
PharmacoEconomics 41 (12), 1557-1561, 2023
Systemet kan inte utföra åtgärden just nu. Försök igen senare.
Artiklar 1–20